If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Luran S MED 797S SPF30 is one of the first ASA materials in the market specifically for medical device housings
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Subscribe To Our Newsletter & Stay Updated
